Testosterone Enanthate and Bupropion Interaction

Why This Combination Is Common

Hypogonadal men present with depression at rates two to four times higher than eugonadal peers. A 2019 cross-sectional analysis of 3,987 men in the European Male Ageing Study found that total testosterone below 8 nmol/L was associated with a 2.1-fold increased odds of depressive symptoms after adjustment for age, BMI, and comorbidities (Fukai et al., 2019). Bupropion is frequently chosen over SSRIs in this population because it avoids sexual side effects that already burden men seeking TRT.

The clinical reality is that prescribers encounter this pair regularly. Both drugs carry FDA labeling that mentions seizure risk, and the CYP2D6 overlap creates a pharmacokinetic wrinkle that few interaction checkers explain clearly. The remainder of this article dissects both pathways.

Pharmacokinetic Interaction: CYP2D6 Inhibition

Bupropion and its active metabolite hydroxybupropion are potent inhibitors of cytochrome P450 2D6. The FDA label for bupropion hydrochloride states that co-administration increased the AUC of desipramine (a CYP2D6 substrate) by approximately 5-fold (FDA Wellbutrin SR Label). That degree of inhibition classifies bupropion as a strong CYP2D6 inhibitor per FDA guidance.

Testosterone itself is primarily metabolized by CYP3A4 and 5α-reductase, with CYP2D6 playing a secondary role in the oxidation of certain androgenic metabolites. A 2004 in-vitro study demonstrated that CYP2D6 contributes to the 6β-hydroxylation of testosterone, accounting for roughly 10-15% of total hepatic clearance (Niwa et al., 2015). This means bupropion's CYP2D6 blockade does not halt testosterone metabolism, but it may modestly raise circulating testosterone and dihydrotestosterone (DHT) levels by 10-20% in CYP2D6 extensive metabolizers.

The practical consequence: men who are already at the upper end of their target testosterone range (e.g., trough levels 700-900 ng/dL) could drift into supraphysiologic territory after bupropion initiation. This won't happen in every patient. CYP2D6 poor metabolizers (7-10% of Caucasians) already have reduced 2D6 activity, so bupropion adds minimal incremental inhibition in that subgroup.

Pharmacodynamic Interaction: Seizure Threshold

This is the interaction that matters more clinically. Bupropion carries a dose-dependent seizure risk: 0.1% at doses ≤300 mg/day, rising to 0.4% at 450 mg/day per the FDA prescribing information (FDA Wellbutrin SR Label). The mechanism involves norepinephrine and dopamine reuptake inhibition, which increases cortical excitability.

Testosterone and its metabolites have documented neuroexcitatory properties. Anabolic-androgenic steroids reduce GABAergic inhibition in animal models, and a 2006 study in Psychoneuroendocrinology demonstrated that supraphysiologic testosterone doses (600 mg/week) significantly lowered seizure thresholds in male rats (Penatti et al., 2006). Human data are limited to case reports, but the Endocrine Society's 2018 guideline on testosterone therapy notes that clinicians should exercise caution with co-prescribed drugs that lower seizure threshold (Bhasin et al., 2018).

The combined effect is additive, not synergistic. No published case series has reported excess seizures specifically in the testosterone-plus-bupropion combination. But the theoretical risk is real enough that the interaction appears in Lexicomp and Micromedex as "monitor therapy."

Severity Classification Across DDI Databases

Different drug interaction databases rate this pair slightly differently:

Lexicomp assigns a "C" rating (Monitor Therapy) to the pharmacodynamic seizure-threshold interaction. Clinical Pharmacology rates the combination as "moderate" severity. DrugBank flags the CYP2D6 component but does not separately flag the seizure risk. The FDA labels for both drugs do not specifically name each other, but both carry seizure-related warnings that overlap.

The consensus: this is not a contraindicated combination. It requires informed prescribing, baseline risk assessment, and follow-up labs.

Who Is at Higher Seizure Risk

Not all patients carry equal risk. The bupropion FDA label identifies specific risk factors for seizures that should be screened before adding TRT (FDA Wellbutrin SR Label):

History of seizure disorder or head trauma with loss of consciousness. Active eating disorder (bulimia or anorexia). Concurrent use of other drugs that lower seizure threshold (tramadol, theophylline, systemic corticosteroids). Abrupt discontinuation of alcohol or benzodiazepines. Bupropion doses exceeding 450 mg/day. Metabolic abnormalities including hyponatremia and hypoglycemia.

If a patient has zero additional risk factors, the combination is generally well-tolerated at standard doses (testosterone enanthate 100-200 mg weekly or biweekly; bupropion ≤300 mg/day). If one or more risk factors are present, the prescriber should either choose an alternative antidepressant or maintain bupropion at the lowest effective dose with documented informed consent.

Monitoring Protocol for Co-Prescription

A structured monitoring approach reduces risk. The following timeline reflects consensus from the Endocrine Society's 2018 testosterone therapy guideline and bupropion labeling (Bhasin et al., 2018):

Baseline (before starting the combination): Total testosterone (trough), free testosterone, SHBG, hematocrit, PSA (men over 40), hepatic panel, seizure history screen, and current medication reconciliation for other CYP2D6 substrates.

Week 4-6: Repeat total and free testosterone at trough. If levels have risen more than 20% above the pre-bupropion baseline without a dose change in testosterone enanthate, the CYP2D6 interaction is clinically relevant for that patient. Consider reducing testosterone dose by 10-20%.

Week 8-12: Hematocrit check. Polycythemia (hematocrit >54%) may emerge faster if testosterone levels are running higher than expected. Hepatic panel if baseline was abnormal.

Ongoing (every 6-12 months): Standard TRT monitoring per Endocrine Society guidelines, with specific attention to any new seizure risk factors (alcohol use changes, new medications, metabolic derangements).

Dose Adjustment Strategies

Most clinicians do not empirically reduce either drug's dose at initiation. Instead, they monitor and react. However, two scenarios warrant preemptive adjustment:

Scenario 1: The patient is already on testosterone enanthate 200 mg/week with a trough total testosterone of 850-950 ng/dL. Adding bupropion may push levels supraphysiologic. Reducing testosterone to 160-180 mg/week before or concurrent with bupropion initiation prevents overshoot.

Scenario 2: The patient has one seizure risk factor (e.g., prior concussion). Capping bupropion at 150 mg/day (the SR once-daily dose) while maintaining standard testosterone dosing is a conservative approach supported by the dose-response seizure data in the FDA label.

There is no published RCT guiding these adjustments. They represent expert consensus and extrapolation from pharmacokinetic principles.

Effect on Bupropion's Metabolites

A less-discussed aspect: testosterone enanthate is a weak inducer of certain hepatic enzymes at supraphysiologic doses. In a 2002 pharmacokinetic study, men receiving testosterone 300 mg/week showed 12% higher clearance of antipyrine, a non-specific CYP probe substrate (Minto et al., 1997). Whether this marginally increases bupropion's metabolism to hydroxybupropion (which retains both antidepressant and CYP2D6 inhibitory activity) is not well-characterized.

The clinical relevance is likely minimal at replacement doses of testosterone (100-200 mg/week). At supraphysiologic doses used in bodybuilding contexts (500+ mg/week), the picture changes, but that falls outside medical TRT parameters.

Impact on Depression Outcomes

Combining TRT with bupropion may offer additive antidepressant benefit. A 2019 randomized placebo-controlled trial (TTriOS, N=788) found that testosterone gel improved depressive symptoms measured by PHQ-9 in hypogonadal men, with the largest effect in those with baseline PHQ-9 scores ≥10 (Snyder et al., 2016). Bupropion's efficacy in major depression is well-established, with NNT of approximately 7 versus placebo in meta-analyses.

No head-to-head trial has compared testosterone monotherapy versus bupropion versus the combination for depression in hypogonadal men. The rationale for combining them is mechanistic: testosterone addresses the neuroendocrine deficit while bupropion provides dopaminergic/noradrenergic support. Both preserve sexual function, making the pair particularly suitable for men whose depression includes low libido as a prominent symptom.

Alternative Antidepressants With Fewer Interaction Concerns

If the seizure risk profile is unfavorable, prescribers should consider:

Mirtazapine: no CYP2D6 inhibition, no seizure threshold reduction, and may improve sleep. The weight gain side effect can be beneficial in cachectic hypogonadal men but problematic in those with metabolic syndrome.

Sertraline: mild CYP2D6 inhibition only at doses above 150 mg/day. Lower seizure risk than bupropion. However, SSRI-associated sexual dysfunction may undermine the libido benefits of TRT.

Vortioxetine: minimal CYP2D6 effect, no seizure signal, and favorable sexual side effect profile (Jacobsen et al., 2015). Higher cost limits access for some patients.

Patient Counseling Points

Men starting this combination should receive specific counseling:

Report any new-onset tremor, myoclonic jerks, or unusual sensory phenomena (auras) immediately. These may precede seizure activity. Do not exceed the prescribed bupropion dose or split tablets to modify release characteristics. Maintain consistent alcohol intake patterns. Abrupt alcohol cessation while on bupropion is a recognized seizure trigger. Report symptoms of polycythemia: headache, visual changes, facial flushing, or dizziness. These could indicate hematocrit elevation from increased testosterone exposure. Do not add over-the-counter stimulants (ephedrine, high-dose caffeine) without discussing with the prescribing clinician, as these further lower seizure threshold.

Hematologic Considerations

Testosterone's stimulation of erythropoiesis is dose-dependent. The FDA label for testosterone enanthate (Delatestryl) identifies polycythemia as the most common adverse effect, occurring in 5.4% of men on replacement doses (FDA Delatestryl Label). If bupropion's CYP2D6 inhibition raises effective testosterone exposure by 10-20%, the polycythemia risk correspondingly increases.

The Endocrine Society recommends hematocrit monitoring at 3-6 months after TRT initiation and annually thereafter. For men co-prescribed bupropion, checking hematocrit at 6-8 weeks captures any accelerated erythropoietic response. Therapeutic phlebotomy or dose reduction is indicated if hematocrit exceeds 54%.

Summary of Evidence Quality

The CYP2D6 interaction is mechanistically sound but lacks dedicated clinical PK studies measuring testosterone levels before and after bupropion initiation. The seizure threshold interaction rests on animal data, case reports, and pharmacological reasoning rather than controlled human trials. No published meta-analysis or systematic review specifically addresses this drug pair. The monitoring recommendations derive from extrapolation of the Endocrine Society guideline and the bupropion FDA label, applied to the overlapping risk profile.

This evidence gap does not mean the interaction is clinically irrelevant. It means the standard of care is vigilant monitoring rather than avoidance. Clinicians should document their risk-benefit assessment when co-prescribing.

Standard testosterone enanthate doses (100-200 mg IM every 1-2 weeks) paired with bupropion ≤300 mg/day carry a low absolute risk of adverse interaction when seizure risk factors are absent and hematocrit is monitored at 6-8 weeks post-initiation.